Sanofi Pasteur announced that Fluzone influenza vaccines for the 2016–2017 season has shipped.
Currently, the Centers for Disease Control and Prevention (CDC) recommends annual influenza vaccination for individuals aged ≥6 months, with rare exception. Starting July, over 65 million doses will be delivered to healthcare providers and pharmacies until the remainder of the year.
Fluzone High-Dose vaccine, an inactivated influenza vaccine, is intended for individuals ≥65 years. it contains 4 times the antigen of Fluzone vaccine to promote a stronger immune response to influenza. Fluzone Quadrivalent vaccine helps protect against two influenza A strains and two influenza B strains; the B strain is associated with substantial hospitalization and mortality. This is the first 4-strain influenza vaccine approved for use in individuals ≥6 months. Fluzone Intradermal Quadrivalent vaccine is indicated for use in adults 18–64 years. It also offers 4-strain protection via administration directly into the skin.
Healthcare providers who reserved vaccine orders through Sanofi Pasteur should expect to receive initial shipments between late July and early August.
For more information call (800) VACCINE or visit Fluzone.com.